Our doctors are seeing patients at our locations and through video visits. Schedule an appointment online or call your doctor’s office. To see a provider as soon as possible, use Virtual Urgent Care. Learn more about how we’re keeping you safe.

Skip to main content

Mila B. Ortigoza, MD, PhD

  • Specialty: Infectious Diseases
  • Language: English
  • Phone: 646-501-9831
View Locations

Education and Training
  • Fellowship, NYU School of Medicine, Infectious Disease, 2017
  • Residency, NYU School of Medicine, Internal Medicine, 2015
  • MD from Mount Sinai School of Medicine, 2013
  • PhD from Mount Sinai School of Medicine, 2011

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Agewell
    • Agewell
  • Amidacare
    • Amidacare
  • Centerlight
    • Centerlight
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Emblem
    • Emblem Select Care Exchange
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield HealthPlus
    • Empire Blue Cross Blue Shield HealthPlus Essential
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
    • GHI HMO
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Locations and Appointments

NYU Infectious Disease Associates

530 1st Avenue, HCC Suite 7F
New York, NY 10016

Interests

influenza, streptococcus pneumoniae

  • Convalescent Plasma To Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing The Efficacy And Safety Of Anti-Sars-Cov-2 Plasma To Placebo In Covid-19 Hospitalized Patients

    Learn More
View All Research Studies (1)

Read All Publications (6)

Related News